Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 7/7/17 → 6/9/21 |
Financiación
- AbbVie Incorporated: 46.860,00 US$
M15-991 a MultiCenter Randomized Double Blind Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Chron's Disease Who Failed Prior Biologic Treatment
- Flomenhoft, Deborah (PI)